2010
Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures
Bernheim SM, Wang Y, Bradley EH, Masoudi FA, Rathore SS, Ross JS, Drye E, Krumholz HM. Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. American Heart Journal 2010, 160: 943-950.e5. PMID: 21095284, PMCID: PMC3319386, DOI: 10.1016/j.ahj.2010.06.046.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsCross-Sectional StudiesFemaleHospitalizationHumansMaleMedicaidMedicareMyocardial InfarctionOutcome and Process Assessment, Health CarePlatelet Aggregation InhibitorsPrognosisQuality ImprovementQuality Indicators, Health CareRetrospective StudiesUnited StatesConceptsAcute myocardial infarctionProportion of patientsRelative contraindicationAngiotensin-converting enzyme inhibitorTreatment of patientsMedicaid Services core measuresQuality improvement projectPublic reportingCross-sectional analysisMyocardial infarctionMedicare patientsHospital careΒ-blockersAMI admissionsPatientsInsufficient evidenceEnzyme inhibitorsTreatment ratesBetter careContraindicationsMedicaid ServicesData cohortCore measuresTreatmentImprovement project
1997
Warfarin use among patients with atrial fibrillation.
Brass L, Krumholz H, Scinto J, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28: 2382-9. PMID: 9412618, DOI: 10.1161/01.str.28.12.2382.Peer-Reviewed Original ResearchConceptsAtrial fibrillationAdditional vascular risk factorsConnecticut Peer Review OrganizationRate of strokeVascular risk factorsStroke preventionWarfarin anticoagulationChart reviewElderly patientsRelative contraindicationPeer review organizationsRisk factorsMedicare patientsAnticoagulationHigh riskPatientsWarfarinFibrillationStrokeContraindicationsAspirinReview organizationsPopulation sampleHospitalizationMonths